A
ASCENDIS PHARMA AS
NASDAQ: ASND (Ascendis Pharma A/S)
Last update: 8 hours ago175.78
-1.12 (-0.63%)
| Previous Close | 176.90 |
| Open | 177.25 |
| Volume | 297,482 |
| Avg. Volume (3M) | 497,951 |
| Market Cap | 10,633,670,656 |
| Price / Sales | 24.50 |
| 52 Weeks Range | |
| Earnings Date | 1 Sep 2025 - 5 Sep 2025 |
| Profit Margin | -92.67% |
| Operating Margin (TTM) | -103.23% |
| Diluted EPS (TTM) | -6.66 |
| Quarterly Revenue Growth (YOY) | 5.30% |
| Current Ratio (MRQ) | 1.04 |
| Operating Cash Flow (TTM) | -218.93 M |
| Levered Free Cash Flow (TTM) | -133.44 M |
| Return on Assets (TTM) | -22.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Ascendis Pharma A/S | Bullish | Bullish |
AIStockmoo Score
1.6
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -4.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 1.63 |
|
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.78% |
| % Held by Institutions | 113.56% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Westfield Capital Management Co Lp | 31 Mar 2025 | 5,479,259 |
| Avoro Capital Advisors Llc | 31 Mar 2025 | 5,218,000 |
| Janus Henderson Group Plc | 31 Mar 2025 | 4,486,949 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 280.00 (Evercore ISI Group, 59.29%) | Buy |
| Median | 220.00 (25.16%) | |
| Low | 200.00 (Cantor Fitzgerald, 13.78%) | Buy |
| Average | 229.63 (30.64%) | |
| Total | 8 Buy | |
| Avg. Price @ Call | 169.67 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Oppenheimer | 13 Jun 2025 | 224.00 (27.43%) | Buy | 170.80 |
| B of A Securities | 09 Jun 2025 | 216.00 (22.88%) | Buy | 173.15 |
| 03 Jun 2025 | 201.00 (14.35%) | Buy | 174.40 | |
| Cantor Fitzgerald | 12 May 2025 | 200.00 (13.78%) | Buy | 154.43 |
| Morgan Stanley | 05 May 2025 | 250.00 (42.22%) | Buy | 170.74 |
| Evercore ISI Group | 02 May 2025 | 280.00 (59.29%) | Buy | 172.06 |
| JP Morgan | 02 May 2025 | 245.00 (39.38%) | Buy | 172.06 |
| RBC Capital | 02 May 2025 | 210.00 (19.47%) | Buy | 172.06 |
| 16 Apr 2025 | 205.00 (16.62%) | Buy | 158.15 | |
| Wedbush | 02 May 2025 | 212.00 (20.61%) | Buy | 172.06 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |